Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of HRS-4357 in PSMA-positive advanced prostate cancer
CTR20232716Phase 2Active
- Sponsor
- Hengrui Pharma
- Start
- Dec 2023
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-4357 in prostate cancer (PCa), sponsored by Hengrui Pharma. Started Dec 2023; status: active.
02
Drugs
HRS-4357
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20232716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232716.